Surgery in breast cancer patients may trigger a negative response in the body that allows dormant cancer cells to thrive. However, according to a new study published in Science Translational Medicine, new research suggests taking a non-steroidal anti-inflammatory drug (NSAID) around the time of surgery could help stop such growth in its tracks.

Researchers from the University of Adelaide have developed a microscopic probe capable of measuring temperatures while viewing the inside of the body. Study findings were published in the upcoming April 15 Optics Letters.

A recent article published in Current Problems in Diagnostic Radiology takes Stephen R. Covey’s eight habits of highly effective people and applies them to radiology, while adding a ninth.

Disparities remain in the impact of cardiovascular disease (CVD) around the United States—mostly due to risk factors that can be changed, according to new research published April 11 in JAMA Cardiology.

The Rush hospital system based in Chicago has ended plans to acquire Little Company of Mary of Evergreen Park, Illinois, which would’ve merged 12 facilities with Rush University Medical Center and its 2,500-student health sciences college.

Johnny Delashaw, MD, the former chief of the Swedish Neuroscience Institute (SNI), is suing the Seattle Times over what he alleges was a “false and defamatory” investigative article that damaged his reputation and led to his resignation and the suspension of his medical license.

A decision made by the U.S. Department of Justice (DOJ) to formally withdraw four Advance Notices of Proposed Rulemaking related to Titles II and III of the Americans with Disabilities Act (ADA) has halted national efforts to ensure individuals with disabilities have access to medical diagnostic equipment, including medical imaging equipment.

The report from the Health Care Cost Institute (HCCI) examined claims for people with multiple sclerosis (MS) from 2009 to 2015 covered by individual market, employer-sponsored or Medicare Advantage plans. It found total spending per MS patient rose from around $23,900 to $39,628 by 2015. During the same time period, the share of spending spent towards injectable and oral disease modifying therapies (DMTs) rose from 39 percent to 53 percent.